Tag: medtronic
Simona Zannetti returns to Medtronic to lead aortic business
Medtronic recently announced that Simona Zannetti has been appointed as the general manager of i...
Amazon executive joins Medtronic to spearhead development in robotics and implantables
Medtronic has announced that Ken Washington has been appointed chief technology and innovation offic...
AHA 2022: SPYRAL HTN-ON MED study demonstrates “meaningful clinical benefits” consistent with other renal denervation trials
Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clin...
Medtronic expands US rollout of Evolut FX TAVI system
Medtronic has announced the expanded US market release of its newest-generation, self-expanding tran...
Medtronic launches Onyx Frontier coronary stent following CE mark approval
Medtronic has announced the launch of its latest generation drug-eluting coronary stent—Onyx Frontie...
Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition
Medtronic today announced it has entered into a strategic partnership agreement with CathWorks, a pr...
Medtronic names Laura Mauri as new chief scientific, medical and regulatory officer
Medtronic has announced that Laura Mauri has been appointed as the company’s chief scientific, medic...
ADVERTORIAL: Evolut PRO+ provides options in the toughest TAVI cases
This advertorial is sponsored by Medtronic.
Evolut PRO+ is the latest generation of self-expandin...
TCT 2021: Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study
Medtronic has announced findings from a new study of patient preferences for the treatment of hypert...
EuroPCR 2021: Late-breaking data demonstrate long-term benefits of Medtronic radiofrequency renal denervation in real-world hypertensive patients
Medtronic today announced new clinical data from the Global SYMPLICITY registry (GSR) indicating...
Resolute Onyx becomes first and only drug-eluting stent in Europe to have one-month DAPT indication for high bleeding risk patients
Medtronic has received the CE mark for a one-month dual antiplatelet therapy (DAPT) indication f...
Jeffrey J Popma joins Medtronic as vice president and chief medical officer for coronary, renal denervation, and structural heart businesses
Medtronic has that announced Jeffrey J Popma (Harvard Medical School; Beth Israel Deaconess Medical ...
SCAI 2020: Strong 10-year performance for Melody transcatheter pulmonary valve
A late-breaking clinical trial presented at the virtual Society for Cardiovascular Angiography a...
Resolute Onyx matches Orsiro at two years in all-comers’ patients
Two-year data from the BIONYX trial show that all-comer patients who underwent percutaneous coro...
COVID-19: Ventilator manufacturers unite to training alliance and create app for frontline workers
A press release reports that several of the world’s ventilator manufacturers have formed a Ventilato...
Virtual ACC: Medtronic shares positive results of Onyx ONE Clear Study
Medtronic today announced positive results of the Onyx ONE Clear Study that evaluated the Resolu...
FDA approves Evolut PRO+
The US Food and Drug Administration (FDA) has approved the Evolut PRO+ transcatheter aortic valv...
FDA approves Sapien 3 Ultra, Sapien 3, and CoreValve for low-risk TAVI
On 16 August, the US Food and Drug Administration (FDA) approved Edwards Lifesciences’ Sapien 3 ...
Medtronic enters into AI partnership for stroke care
Medtronic has entered into a partnership agreement with Viz.ai to accelerate the adoption of art...
Medtronic launches Telescope guide extension catheter
Medtronic recently announced the global launch of the Telescope guide extension catheter, a newl...
Targeted blood pressure management helps to reduce strokes in patients with HVAD
An analysis on the impact of stroke severity in patients receiving the HeartWare HVAD system (Me...
ACC 2019: TAVI moves to the mainstream with new findings in low-risk patients
Evidence for the use of transcatheter aortic valve replacement (TAVI) as standard therapy is mountin...
CRT 2019: Evolut R superior to surgery at one year in intermediate-risk patients
A subanalysis from the SURTAVI trial has found that transcatheter aortic valve implantation (TAV...
US physicians can now use Resolute to treat chronic total occlusions
Medtronic has received US FDA approval of its Resolute drug-eluting stent platform—including the...
US FDA approve new study of Medtronic’s Spyral renal denervation system
The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyra...
TCT 2018: Longest-term data to date for CoreValve study show excellent valve durability out to five years
New data presented at 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 Septem...
US FDA approve study of CoreValve Evolut in low-risk patients with bicuspid valves
The US FDA has approved an investigational device exemption (IDE) to initiate a single-arm study...
US FDA approval for SynchroMed II implantable system for treating pulmonary arterial hypertension
Medtronic has received US FDA approval for its implantable system for Remodulin to treat patients wi...
US FDA classifies HeartWare HVAD power issues as a Class I recall
The US FDA has classified Medtronic’s recent voluntary urgent field action related to the HeartW...
Use of Resolute Onyx to be explored for the treatment of bifurcation lesions
Medtronic has announced the initiation of a clinical study in the US to assess the safety and ef...
Medtronic appoints Laura Mauri as vice president, Global Clinical Research & Analytics
Medtronic has announced that Laura Mauri—interventional cardiologist and clinical researcher at the ...
Following FDA approval, Resolute Onyx 2mm becomes smallest stent on US market
Designed specifically for small vessels, the Resolute Onyx 2mm drug-eluting stent has received U...
“We really believe that the transradial approach is a better way to do cardiac catheterisations”
The Society for Cardiovascular Angiography and Interventions (SCAI) has launched a new initiativ...
First patient implanted with Intrepid TMVI device in APOLLO trial
The first patient in the APOLLO trial has undergone transcatheter mitral valve implantation (TMV...
Medtronic HeartWare HVAD approved for destination therapy
The US Food and Drug Administration (FDA) has approved Medtronic’s HeartWare HVAD system as a de...
From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal denervation
It is now almost a decade since the first patient underwent catheter-based renal denervation as ...
FORWARD PRO clinical study to evaluate longer term performance of CoreValve Evolut Pro
A new post-market clinical study is to evaluate Medtronic’s CoreValve Evolut Pro transcatheter a...
ESC 2017: SPYRAL HTN-OFF MED provides “proof of principle” that renal denervation works
Results from SPYRAL HTN-OFF MED indicate that renal denervation, compared with a sham procedure,...
Medtronic to undertake global randomised clinical trial of one-month DAPT in Resolute Onyx patients
Medtronic has announced a global randomised clinical trial that will evaluate one-month dual ant...
Medtronic’s Avalus pericardial valve receives CE mark and FDA approval
Medtronic has announced CE mark and FDA approval of its new Avalus pericardial aortic surgical v...
CE mark for CoreValve Evolut Pro
Medtronic has received the CE mark for its CoreValve Evolut Pro valve for the treatment of sever...
Medtronic releases Resolute Onyx drug-eluting stent in Japan
Medtronic will release the Resolute Onyx coronary stent system in Japan. According to a press re...
EuroPCR 2017: No stent thrombosis with Resolute Onyx drug-eluting stent 2mm
Data for the Resolute Onyx drug-eluting 2mm stent (Medtronic), which were presented at EuroPCR ...
EuroPCR 2017: Excellent clinical outcomes for Medtronic’s CoreValve and Evolut systems in routine practice
New positive data on the self-expanding Medtronic CoreValve platform from the CoreValve ADVANCE ...
FDA approves Medtronic’s Resolute Onyx drug-eluting stent
The FDA has approved Medtronic’s Resolute Onyx drug-eluting stent, which the company has now lau...
US FDA designates Medtronic HVAD system controller field action as class I recall
The US Food and Drug Administration (FDA) has classified Medtronic’s recently initiated voluntar...
LATERAL study offers positive overall results for Medtronic HVAD
Preliminary results from the Medtronic -sponsored HVAD LATERAL study have demonstrated overall p...
Medtronic ENDURANCE Supplemental trial of HVAD fails to meet primary endpoint
Medtronic’s ENDURANCE Supplemental trial of the company’s HVAD ventricular assist device has fai...
TAVI pacemaker issue is “an engineering problem that will be solved”
The SURTAVI trial indicates that transcatheter aortic valve implantation (TAVI) with CoreValve/...
ACC 2017: CoreValve non-inferior to surgery in intermediate-risk patients
Results from the SURTAVI clinical trial, which were presented today at the 2017 scientific sessi...
Medtronic launches Impact education and development programme in Europe, Middle East & Africa
Medtronic has announced the launch of Medtronic Impact in the Europe, Middle East & Africa regio...
Medtronic releases DxTerity diagnostic catheters and transradial approach tool
Medtronic has launched the DxTerity diagnostic angiography catheter line, and several ...
Medtronic receives CE mark for 34mm size CoreValve Evolut R
The CE mark has been granted to Medtronic for the 34mm-valve version of its CoreValve Evolut R, ...
Japan’s Ministry of Health, Labor and Welfare approves reimbursement for Medtronic’s CoreValve Evolut R system
Medtronic has been granted reimbursement approval from the Japanese Ministry of Health, Labor an...
Medtronic first to receive CE mark for less-invasive HVAD implant procedure
Medtronic’s HVAD system left ventricular assist device (LVAD) has received the CE mark for a les...
TCT 2016: First-in-human data shows Medtronic’s drug-filled stent to be non-inferior to Resolute
Results of the REVELUTION study, simultaneously presented at the 2016 Transcatheter Cardiovascul...
FDA approval of 34mm CoreValve Evolut R means device is largest available TAVI valve in USA
Medtronic has announced the FDA approval and US launch of the CoreValve Evolut R 34mm valve—the ...
Health Canada grants licence to Medtronic for its CoreValve Evolut R system
Medtronic Canada has announced it has received a Health Canada licence for its recapturable, sel...
EACTS 2016: Positive one-year outcomes for Medtronic’s surgical aortic valve Avalus
Positive clinical data for Medtronic’s investigational Avalus pericardial aortic surgical valve were...
Medtronic ranks on Dow Jones Sustainability North America Index for ninth consecutive year
Medtronic has been recognised as one of the world's leading companies for sustainability, rankin...
Purchase of HeartWare by Medtronic completed
Medtronic has completed its acquisition of HeartWare International—a developer of less-invasive,...
Renal denervation devices are alternatives to drug therapy, Technavio reports
Analysts from Technavio have forecast the global renal denervation market to grow at a compound annu...
Medtronic CoreValve Evolut becomes first TAVI to receive CE mark for intermediate risk aortic stenosis patients
Medtronic has received CE marking for the self-expanding, recapturable and repositionable CoreValv...
